Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA.

N Engl J Med. 1993 Jul 15;329(3):162-7.

2.

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J.

J Clin Psychiatry. 1998;59 Suppl 3:3-7. Review.

3.

[Hepatic tolerance of atypical antipsychotic drugs].

Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D.

Encephale. 2002 Nov-Dec;28(6 Pt 1):542-51. Review. French.

PMID:
12506267
4.

Clozapine: the commitment to patient safety.

Alphs LD, Anand R.

J Clin Psychiatry. 1999;60 Suppl 12:39-42. Review.

5.

Clozapine-associated agranulocytosis: risk and aetiology.

Krupp P, Barnes P.

Br J Psychiatry Suppl. 1992 May;(17):38-40. Review.

PMID:
1418887
6.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
7.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
8.

Suicide in schizophrenia: risk factors and clozapine treatment.

Meltzer HY.

J Clin Psychiatry. 1998;59 Suppl 3:15-20. Review.

9.

Maximizing clozapine therapy: managing side effects.

Lieberman JA.

J Clin Psychiatry. 1998;59 Suppl 3:38-43. Review.

10.

Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.

Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF.

J Clin Psychiatry. 2012 Oct;73(10):1307-12. doi: 10.4088/JCP.11r06977. Review.

PMID:
23140648
11.

[The atypical neuroleptic clozapine (Leponex)--current knowledge and recent clinical aspects].

Klimke A, Klieser E.

Fortschr Neurol Psychiatr. 1995 May;63(5):173-93. Review. German.

PMID:
7782019
12.

[Leponex, 10 years after -- a clinical review].

Llorca PM, Pere JJ.

Encephale. 2004 Sep-Oct;30(5):474-91. Review. French.

PMID:
15627052
13.

Clozapine: a clinical review of adverse effects and management.

Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM.

Ann Clin Psychiatry. 2003 Mar;15(1):33-48. Review.

PMID:
12839431
14.
15.

[Clozapine--an atypical antipsychotic agents, its advantages and risks].

Zvolský P, Hulínský J.

Cesk Psychiatr. 1994 Dec;90(6):328-40. Review. Czech.

PMID:
7859323
16.

[Clozapine].

Inada K, Ishigooka J.

Nihon Rinsho. 2013 Apr;71(4):678-83. Review. Japanese.

PMID:
23678599
17.

[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors].

van Melick EJ, Touw DJ, Haak HL.

Ned Tijdschr Geneeskd. 1995 Nov 25;139(47):2437-40. Review. Dutch.

PMID:
8524426
18.

Review and management of clozapine side effects.

Miller DD.

J Clin Psychiatry. 2000;61 Suppl 8:14-7; discussion 18-9. Review.

19.

Clozapine: a novel antipsychotic.

Buch DL.

Am Fam Physician. 1992 Feb;45(2):795-9. Review.

PMID:
1739062
Items per page

Supplemental Content

Write to the Help Desk